Krebs Biochemicals & Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021
For the nine months, sales was INR 351.36 million compared to INR 255.32 million a year ago. Revenue was INR 409.09 million compared to INR 380.18 million a year ago. Net loss was INR 332.13 million compared to INR 213.72 million a year ago. Basic loss per share from continuing operations was INR 15.42 compared to INR 10.89 a year ago. Diluted loss per share from continuing operations was INR 15.42 compared to INR 10.89 a year ago.